Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Immunomedics, Inc.
  6. Summary
    IMMU   US4529071080

IMMUNOMEDICS, INC.

(IMMU)
 SummaryChartsNewsRatingsCompany 
Quotes 5-day view   End-of-day quote. End-of-day quote Nasdaq
03/25/2020 03/26/2020 03/27/2020 03/30/2020 03/31/2020 Date
12.58 13.23 12.84 13.76 13.48 Last
3311740 2851218 2328982 1734237 2548614 Volume
-2.48% +5.17% -2.95% +7.17% -2.03% Change
Company
Immunomedics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing monoclonal antibody-based products for the targeted treatment of cancer. Its technologies allow it to create humanized antibodies that can be used either alone in unlabeled or naked form, or conjugated with radioactive isotopes, chemotherapeutics, cytokines or toxins. It has a pipeline of six clinical-stage product... 
More about the company
Ratings of Immunomedics, Inc.
Trading Rating : 
Investor Rating :  -
ESG Refinitiv : 
-
More Ratings
All news about IMMUNOMEDICS, INC.
04/20Protara Therapeutics Announces Appointment of Martin Sebastian Olivo, M.D. as..
AQ
01/11GILEAD SCIENCESá : Raises Product Sales Guidance on Remdesivir Demand, Narrows E..
DJ
2020GILEAD SCIENCESá : Advances Oncology Portfolio with New Data from Phase 3 ASCENT..
AQ
2020GILEAD SCIENCESá : to Pay $1.4 Billion for Hepatitis Drug Maker MYR GmbH of Germ..
DJ
2020GILEAD SCIENCESá : Announces Third Quarter 2020 Financial Results
AQ
2020Gilead Quarterly Revenue Rises on Remdesivir Sales -- Update
DJ
2020GILEAD SCIENCESá : Quarterly Revenue Rises on Remdesivir Sales
DJ
2020GILEAD SCIENCESá : Completes Acquisition of Immunomedics, Inc.
AQ
2020IMMUNOMEDICS INCá : Completion of Acquisition or Disposition of Assets, Notice o..
AQ
2020GILEAD SCIENCESá : Announces Expiration of Hart-Scott-Rodino Waiting Period for ..
AQ
2020IMMUNOMEDICSá : Announces FDA Orphan Drug Designation of Trodelvyᵀᴹ ..
PU
2020IMMUNOMEDICSá : Announces FDA Orphan Drug Designation of Trodelvy™ for Adu..
AQ
2020Immunomedics Announces FDA Orphan Drug Designation of Trodelvy™ for Adu..
GL
2020WEISSLAW LLPá : Reminds MR, IMMU, and BMCH Shareholders About Its Ongoing Invest..
PR
2020WeissLaw LLP Reminds AKCA, IMMU, and MXIM Shareholders About Its Ongoing Inve..
PR
More news
News in other languages on IMMUNOMEDICS, INC.
02/05La banque d'affaires Lazard a vu bondir son bénéfice net en 2020
2020BB Biotech sombre dans le rouge au 3e trimestre, reste à flot sur 9 mois
2020HBM im Halbjahr 2020/21 mit Gewinnsprung - Zuversichtlich ins zweite Halbjahr
2020Aktien New York Schluss: Übernahmen bescheren starken Wochenauftakt
2020Wall Street profite du rebond de la tech
More news
Chart IMMUNOMEDICS, INC.
Duration : Period :
Immunomedics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Managers and Directors
NameTitle
Andrew D. Dickinson President, Treasurer & Director
Loretta M. Itri Chief Medical Officer
Brett A. Pletcher Secretary & Director
Christina Carlson Director & Assistant Secretary
Kurt J. W. Andrews Chief Human Resources Officer
Sector and Competitors
1st jan.Capitalization (M$)
IMMUNOMEDICS, INC.0.00%20 324
MODERNA, INC.90.67%79 980
LONZA GROUP LTD14.63%52 508
IQVIA HOLDINGS INC.33.76%45 934
CELLTRION, INC.-24.79%32 465
SEAGEN INC.-10.75%28 367